GILD — Gilead Sciences, Inc.

Gilead Sciences (GILD) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Product Sales: $7.3 billion, up 4% year-over-year; down 2% from Q3 2024, primarily due to a 60% decline in Veklury sales ($277 million) linked to fewer COVID-19 hospitalizations.
• HIV Sales: $5.3 billion, reflecting 4% growth year-over-year, driven by strong performance from Biktarvy ($3.7 billion, +6%) and Descovy ($701 million, +20%).
• Livdelzi Sales: $100 million in quarterly sales, marking a 35% sequential growth and contributing to a 12% increase in the liver portfolio.
• Non-GAAP EPS: $2.47, with a 22% year-over-year growth. Excluding a $400 million nonrecurring revenue item, adjusted EPS would be $2.22.
• Operating Margin: 50%, reflecting disciplined expense management.

2. Strategic Updates and Business Highlights

• HIV Portfolio: Gilead raised its full-year HIV revenue growth expectation to approximately 5%, despite a projected $900 million headwind from Medicare Part D redesign. The launch of Yeztugo for HIV prevention generated $39 million in Q3, with a total of $54 million since its launch in June.
• Oncology Developments: Trodelvy is being positioned for first-line metastatic triple-negative breast cancer (TNBC) with potential regulatory submissions expected in 2026 based on positive Phase III data.
• Liver Disease: Bulevirtide has been filed for FDA approval for chronic hepatitis delta virus, with expectations for a 2026 launch.
• Cell Therapy: Kite's sales were down 11% year-over-year to $432 million, facing competitive pressures, but the company is focused on expanding treatment centers and advancing its next-generation pipeline.

3. Forward Guidance and Outlook

• 2025 Guidance: Total product sales (excluding Veklury) are expected to be between $27.4 billion and $27.7 billion, with total sales anticipated between $28.4 billion and $28.7 billion. Non-GAAP EPS guidance raised to $8.05 - $8.25.
• Yeztugo: Gilead aims for 90% payer coverage by mid-2026, with expectations for continued growth as access improves.
• Clinical Pipeline: Multiple upcoming product launches and clinical readouts are anticipated, particularly in oncology and HIV.

4. Bad News, Challenges, or Points of Concern

• Veklury Sales Decline: A significant drop in Veklury sales reflects ongoing challenges in the COVID-19 treatment market.
• Cell Therapy Market Pressures: Kite's performance is hindered by competitive headwinds, with a forecasted 10% decline in cell therapy revenue for 2025.
• Medicare Part D Impact: The ongoing redesign is expected to create a $900 million headwind for the HIV business, which could affect future growth.
• Market Volatility: Variability in prescription data for Yeztugo raises concerns about the stability of its early sales trajectory.

5. Notable Q&A Insights

• Yeztugo Launch: Management indicated that Yeztugo is seeing a mix of patient switches and new initiations, with a strong focus on payer coverage and access. The company is optimistic about the product's growth trajectory.
• HIV Market Growth: The HIV treatment and prevention markets are expected to continue growing, with Biktarvy and Descovy leading the charge.
• Regulatory Confidence: Gilead expressed confidence in receiving FDA approval for bulevirtide based on additional data and European market experience.
• Competitive Landscape: Discussions highlighted the competitive pressures in the cell therapy space and the need for continued innovation and market adaptation.

Overall, Gilead reported solid quarterly results driven by its HIV portfolio and new product launches, while navigating challenges in the COVID-19 treatment market and competitive pressures in cell therapy. The company remains optimistic about its future growth prospects and pipeline advancements.